These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1215 related articles for article (PubMed ID: 33119182)

  • 21. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
    Zhang Q; Wang W; Yuan Q; Li L; Wang YC; Chi CZ; Xu CH
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):1-9. PubMed ID: 34821962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis.
    Yang Y; Pang P; Xie Z; Wang N; Liang H; Zhao L
    Transl Cancer Res; 2020 May; 9(5):3231-3241. PubMed ID: 35117689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
    Di Federico A; De Giglio A; Nuvola G; Deiana C; Conci N; Gelsomino F; Ardizzoni A
    Future Oncol; 2021 Nov; 17(32):4415-4424. PubMed ID: 34402681
    [No Abstract]   [Full Text] [Related]  

  • 25. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
    Deng S; Yang Q; Shu X; Lang J; Lu S
    Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
    Matsuo N; Azuma K; Kojima T; Ishii H; Tokito T; Yamada K; Hoshino T
    Invest New Drugs; 2021 Aug; 39(4):1150-1158. PubMed ID: 33483882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
    J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
    Cathcart-Rake EJ; Sangaralingham LR; Henk HJ; Shah ND; Riaz IB; Mansfield AS
    Clin Lung Cancer; 2020 Sep; 21(5):421-427.e2. PubMed ID: 32446852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
    Kong Y; Hong L; Xu XC; Chen YF; Xu J
    PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
    Guo X; Li W; Hu J; Zhu EC; Su Q
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
    Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; Santoni M; Tudini M; Ghidini M; Filetti M; Catino A; Pizzutilo P; Sala L; Occhipinti MA; Citarella F; Russano M; Torniai M; Cantini L; Follador A; Sforza V; Nigro O; Ferrara MG; D'Argento E; Leonetti A; Pettoruti L; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Bertolini F; Della Gravara L; Dal Bello MG; Belderbos RA; De Filippis M; Cecchi C; Ricciardi S; Donisi C; De Toma A; Proto C; Addeo A; Cantale O; Ricciuti B; Genova C; Morabito A; Santini D; Ficorella C; Cannita K
    Clin Lung Cancer; 2020 Nov; 21(6):498-508.e2. PubMed ID: 32680806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer.
    Yu H; Chen P; Xia L; Fu S; Chen C; Zhang X; He L; Zhang B; Zhou Y; Hong S
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34750245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias.
    Yu Y; Chen N; Yu S; Shen W; Zhai W; Li H; Fan Y
    Cancer Res Treat; 2024 Jul; 56(3):751-764. PubMed ID: 38186241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score <50.
    Pham TT; Gordon AS; Chen X; Debono D; Fisch MJ
    Cancer Treat Res Commun; 2023; 37():100769. PubMed ID: 37839181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.